NCT03531151Completed
MRI of Myocardial Infarction
Magnetic Resonance Imaging of Myocardial Infarction
Source: ClinicalTrials.gov · Last updated 8 Sept 2025
Brief summary (registry, in English)
Heart failure (HF) is an enormous health burden affecting approximately 5.1 million people in the US and is the cause of 250,000 deaths each year. Approximately 50% of HF is caused by myocardial ischemia and requires immediate restoration of coronary blood flow to the affected myocardium. However, the success of reperfusion is partly limited by intramyocardial hemorrhage, which is the deposition of intravascular material into the myocardium. Hemorrhagic reperfusion injury has high prevalence and patients have a much greater risk of adverse left ventricular remodeling, risk of fatal arrhythmia, impaired systolic function and are hospitalized at a greater rate. Recent magnetic resonance imaging techniques have improved assessment of reperfusion injury, however, the association between MRI contrasts and reperfusion injury is highly unclear, and lacks specificity to IMH. Improved imaging of IMH and accurate knowledge about its spatial and temporal evolution may be essential for delivery of optimal medical therapy in patients and critical to identify patients most at risk for adverse ventricular remodeling. The overall goal is to investigate the magnetic properties of hemorrhage and develop MRI techniques with improved specificity to hemorrhage. New MRI techniques permit noninvasive assessment of the magnetic susceptibility of tissues and can target tissue iron. Therefore, the investigators hypothesize that MRI imaging of myocardial magnetic susceptibility can map hemorrhagic myocardium. The investigators will perform a longitudinal observational study in patients after reperfusion injury to validate these methods, compare the methods with conventional MR contrasts and develop MR methods for imaging humans.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 14 (actual)
- First submitted
- 8 May 2018
- Start date
- 1 Apr 2018
- Primary completion date
- 31 Mar 2025
- Lead sponsor
- University of Pennsylvania
- Diseases
- Heart failure, Coronary artery disease
- NCT number
- NCT03531151
What you commit to
- Study type: Observational
- Participants enrolled: 14
- From 1 Apr 2018 to the primary completion date, 31 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- contraindications to cardiac MRI, including claustrophobia
- advanced renal disease (estimated glomerular filtration rate 30 mL/min) or hypersensitivity to gadolinium
- presence of a cardiac pacemaker or implanted cardiac cardioverter defibrillator
- personal or family history of hypertrophic cardiomyopathy
- history of seizure disorder
Other
- pregnancy
- inability to provide informed consent
Who the study is looking for
- Between the ages of 18 and 80
- Patients must be able to read and understand English
- Participants must sign the informed consent form
- Elevated and delayed peak creatine kinase-MB and troponin I (cTnI) and troponin T (cTnT) in blood serum,
- ST elevation detected on ECG
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.